Searched for
DILIP SHANGHVI STATEMENT
Ram Shriram's Sherpalo Ventures to lead $60 million funding round in Skyroot; valuation hits $1.1 billionGIC, of Singapore, BlackRock, Greenko Group founders take part in round along with Sun Pharma founder Dilip Shanghvi family office as the 9...- Kirti Ganorkar: Why the veteran insider is the right dose for Sun PharmaKirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, wh...
- US tariffs won't hurt Indian pharma and steel exports: TycoonsIndian pharmaceutical and steel sectors show resilience against proposed US trade tariffs. Sun Pharma's Shanghvi indicates limited impact o...
- Govt slaps fine on Sun Pharma officials over related party transactionsSun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failure to obtain necessar...
- Govt slaps fine on Sun Pharma officials over related party transactionsSun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failure to obtain necessar...
- Tata Sons, TVS Motor, 5 other cos launch Indian Foundation for Quality ManagementIndian Foundation for Quality Management, led by prominent industry figures, strives to enhance quality and innovation in Indian businesses...
- Suzlon Energy shares fall over 3% after Dilip Shanghvi and Associates terminate 2020 pactShares of Suzlon Energy fell 3% to Rs 25 in Wednesday's trade on BSE after the Sun Pharma promoter Dilip Shanghvi and Associates decided to...
- Dilip Shanghvi & Associates terminate 2020 pact with Suzlon EnergyWith the termination of the agreement, the investor group's nominee director on Suzlon's board, Hiten Timbadia, has also resigned with effe...
- Sun Pharma names Aalok Shanghvi as whole-time directorSun Pharma Board has appointed Aalok Shanghvi as a whole-time director for a five-year term beginning June 1, 2023. Shanghvi, the son of Su...
- There is no diversion of funds at all: Sudhir Valia, director, Sun PharmaSudhir Valia, brother-in-law of Sun Pharma promoter Dilip Shanghvi, in a telephonic chat with Divya Rajagopal, discusses the issues of Adit...
- Sun Pharma rallies 7% as USFDA lifts import alert on Mohali unitThe Mohali facility was inherited by Sun Pharma as part of its acquisition of Ranbaxy Laboratories in 2015.
- Sun Group, Adani among 42 firms to bid for discovered small fields120 bids received for 26 onland contract areas, 14 bids for 8 offshore blocks.
- Dilip Shanghvi, IDFC Bank, Telenor drop plans to set up payments bankThe decision to abandon plans to set up a payments bank was taken as the promoters felt that they lacked adequate physical presence in term...
- Sun Pharma gains nearly 3% as co buys 14 brands from Novartis"This acquisition marks Sun Pharma's foray into the Japanese prescription market and provides us an opportunity to build a larger product p...
- Make In India: Pharma entrepreneurs urge industry to address compliance issuesShanghvi said companies need to move beyond being mere generic players and look to innovate to capture the potential $800-billion pharmaceu...
- Open offer to acquire 26 per cent stake in Suzlon draws poor responseUnder the open offer, Shanghvi and associates had to acquire 26 per cent stake for Rs 2,837 crore in the wind turbine maker.
- Sun Pharma shares tank nearly 9%; top loser on Sensex, Nifty as Daiichi exitsShares of Sun Pharma tanked nearly 9 per cent today, leading to an erosion of Rs 22,262 crore from its market valuation.
- Sun Pharma's Dilip Shanghvi to acquire 23% in Suzlon Energy for Rs 1,800 croreSuzlon’s promoters will retain management control “by virtue of pooling arrangement for voting”, while the Shanghvi family will remain a fi...
- Sun Pharma chief Dilip S Shanghvi expects Ranbaxy deal to be closed by mid-FebruaryDilip S Shanghvi expects the Ranbaxy deal to be concluded by middle of next month while stating that the key challenge before the combined ...
- Sun Pharma denies insider trading charges in Ranbaxy dealSun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...
Load More
